City-RBP4 in healthy people and Stargardt disease type 1 patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-masked, placebo-controlled phase 1 study that examines safety, tolerability, pharmacokinetics, and pharmacodynamics of CITY-RBP4 after single and multiple subcutaneous doses. The trial has three parts: Part A in healthy volunteers receiving single ascending doses, Part B in STGD1 participants receiving single ascending doses, and Part C in STGD1 participants receiving multiple doses. CITY-RBP4 or placebo will be administered, with adaptive design elements to adjust dosing as data accrue. Primary focus is safety and PK/PD; preliminary signals of activity may be explored in STGD1 participants. Enrollment is limited to adults aged 18-45 for Part A, with specific inclusion/exclusion criteria guiding eligibility.

Why it matters

Who can join: the full rules

Key Inclusion Criteria (Part A):

1. Willing and able to provide written informed consent form
2. Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form
3. Generally healthy on medical history, exam, labs, and ECG
4. BCVA 20/25 or better in each eye
5. Serum retinol above protocol threshold
6. Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2
7. Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period
8. Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status

Key Exclusion Criteria (Part A):

1. Clinically significant ocular disease or prior ocular surgery that could interfere with safety assessments
2. History of vitamin A deficiency, malabsorption, or chronic diarrhea
3. Clinically significant cardiac, hepatic, renal, pulmonary, neurologic, or psychiatric disease
4. Positive hepatitis B, hepatitis C, or HIV screening
5. Prior RNAi/oligonucleotide therapy or recent investigational treatment
6. Recent vitamin A-related supplements, retinoids, or medications affecting vitamin A metabolism
7. Pregnancy or breastfeeding, if applicable

Key Inclusion Criteria (Parts B and C)

1. Participants aged 12 to 45 years
2. Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant
3. Minimum BCVA is required in the study eye
4. Subjects must have a defined aggregate atrophic lesion in 1 or both eyes
5. Body weight ≥40 kg
6. Able to complete key ophthalmic safety assessments and comply with study precautions

Key Exclusion Criteria (Parts B and C)

1. Ocular conditions that could confound retinal imaging or safety evaluation
2. Prior ocular gene therapy, stem cell therapy, or retinal implant
3. Vitamin A deficiency or recent prohibited vitamin A-related treatments
4. Recent interventional study participation
5. Clinically significant non-ophthalmic disease, abnormal screening labs/ECG, or positive hepatitis B, hepatitis C, or HIV screening
6. Pregnancy or breastfeeding, if applicable

Where it's running

• Nucleus Network
  Melbourne, Victoria, Australia Recruiting

Study contacts

• Study coordinator: City Therapeutics
• Email: clinicaltrials@citytx.com
• Phone: 857-219-5440

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VG801 gene therapy for Stargardt disease from ABCA4 mutations

  This open-label, first-in-human trial will try a single dose of VG801 gene therapy in people aged 6 and older who have Stargardt disease from two ABCA4 mutations to see if it is safe and helps vision.

  Recruiting Phase 1/2 VeonGen Therapeutics GmbH · Shanghai, Shanghai Municipality · NCT07002398

• Identifying potential participants for Stargardt disease clinical trials

  This study is trying to find people with Stargardt disease who might qualify for upcoming clinical trials by checking if they meet certain criteria, like having specific gene mutations.

  Recruiting at 7 sites Ascidian Therapeutics, Inc · San Francisco, California and 8 other locations · NCT06445322

• Observing the progression of Stargardt Disease Type 1

  This study is tracking how Stargardt Disease Type 1 progresses in about 75 people to better understand the condition and help improve future treatments.

  Recruiting at 20 sites Splice Bio · San Diego, California and 19 other locations · NCT06435000

• ASP2020 eye injection safety in Stargardt-type macular dystrophy

  A small study will test whether a single ASP2020 eye injection is safe and may help people with Stargardt-type macular dystrophy.

  Recruiting at 4 sites Phase 1 Astellas Pharma Inc · Phoenix, Arizona and 3 other locations · NCT07734064

• C.001 for retinal degeneration: a first-in-human dose-escalation safety test

  A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.

  Recruiting at 2 sites Phase 1 Cellio Therapeutics Inc · Beverly Hills, California and 2 other locations · NCT07594236

• Functional visual field and navigation testing for moderate-to-profound inherited retinal disease

  This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.

  Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT07502664

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.